

**Request for Expressions of Interest (EOI)****Request for Expression of Interest for Selection of CRO for
Bioequivalence (BE) Study of Oral Contraceptive Pill**

SL No.	Item	Description
1	Ministry/Division	Ministry of Health & Family Welfare, Health Service Division
2	Agency	Essential Drugs Company Limited (EDCL), Dhaka, Bangladesh
3	Procuring Entity Name	Managing Director, Essential Drugs Company Limited 395-397, Tejgaon Industrial Area, Dhaka-1208, Bangladesh.
4	Procuring Entity District	Dhaka
5	EOI for Selection of	CRO (Contract Research Organization)
6	Title of the Service	Bioequivalence (BE) Study of Oral Contraceptive Pill.
7	EOI Ref. No.	EDCL/Dhaka/EOI/CRO/BE/2026/60
8	Date	09-02-2026
9	Procurement Method	Quality & Cost Based Selection (QCBS)
10	Source of Funds	EDCL Own Fund
12	Publication Date	10-02-2026
13	EOI Closing Date and Time	Date: 03-03-2026, Time: 12:30PM (BST)
14	Brief Description of Assignment	Bioequivalence (BE) Study of Oral Contraceptive Pill for Suhki Tablet, 3 rd generation (Desogestrel USP 150 µg & Ethinyl Estradiol USP 30 µg)
15	Experience, Resources and Delivery Capacity Required	1) At least 2 completed BE studies for hormones with female volunteer experience. 2) CRO must have its own or contract with a bioanalytical laboratory. 3) CRO must have GCP/GLP/ISO certified 4) Accredited from any national or international regulatory body (WHO prequalified or recognised regulatory approvals i.e, USFDA, EMA, MHRA, TGA, etc.)
16	Other Details	Expression of Interest will include brochures detailing experience, staffing, logistics, expertise, and relevant documents for similar assignments, along with resource availability. Copies of the documents establishing the constitution or legal status, registration place, and main place of business; a written power of attorney from the signatory of the EOI authorising the Consulting Firm to act; Bank Solvency Certificate, Bank statements from the last three years. A list of key professionals, a list of similar service experience records, including the employer's name, service location, scope, contract value, start and end dates, as well completions certificate. CRO/Agent should sign and stamp the all pages of TOR and submit the same along with EOI. Marked "Request for Expression of Interest (EOI) for Selection of CRO for Bioequivalence (BE) Study of Oral Contraceptive Pill".
17	Association with other firms	The CRO must associate with the Local Agent as Joint Venture Consortium Association (JVAC)
18	Name of Official Inviting EOI	Mir Md. Shahabuddin
19	Designation of Official Inviting EOI	Dy. General Manager, Procurement (CC) Essential Drugs Company Limited
20	Address of Official Inviting EOI	395-397, Tejgaon Industrial Area, Dhaka-1208, Bangladesh.
21	Contact details of Official Inviting EOI	Phone: 48116110-1(155) E-mail: gm.procurement@edcl.gov.bd Website: www.edcl.gov.bd
22	The procuring entity reserves the right to accept or reject all the Expression of Interest (EOI) without assigning any reason.	

N.B. The detailed scope of the assignment is available in the Terms of Reference (TOR), which is an integral part of this EOI and will be available on the EDCL website: www.edcl.gov.bd.

Dy. General Manager, Procurement (CC)
Essential Drugs Company Limited

TERMS OF REFERENCE (ToR)

For the Selection of "CRO for Bioequivalence (BE) Study of Oral Contraceptive Pill"

1. Overview:

The purpose of this document is to outline the terms of reference for the Selection of "CRO for Bioequivalence (BE) Study of Oral Contraceptive Pill".

Essential Drugs Company Limited (EDCL) is the sole government-owned pharmaceutical company in Bangladesh, functioning under the direct oversight and supervision of the Ministry of Health and Family Welfare. At present, the company is producing a wide range of generic drugs in the form of Tablet (coated/uncoated), Capsule, Dry Syrup, Liquid (Oral & External), Small volume and Large volume Injectable, Ophthalmic, Skin Ointment, Oral Rehydration Salt (ORS), Oral Contraceptive Pill, etc.

Over 10 (Ten) million people are served by these products, including government hospitals, community clinics, civil surgeon offices, family planning centers, Bangladesh Police, Bangladesh Army, ICDDRDB, UNICEF, WHO, different corporations, governments, and semi-government organizations.

2. Objectives:

Bioequivalence (BE) Study of Oral Contraceptive Pill for Suhki Tablet, 3rd generation (Desogestrel USP 150 µg & Ethinyl Estradiol USP 30 µg).

3. Scope of Work:

- Bioequivalence (BE) Study of Oral Contraceptive Pill for Suhki Tablet, 3rd generation (Desogestrel USP 150 µg & Ethinyl Estradiol USP 30 µg).
- BE study on at least 32 subjects.
- The collection of the Reference Drugs List (RDL), the analysis of two cycles, and the preparation of the report consider all of the above issues to complete the study within 4.5 months.
- EDCL officials (two members) must visit the CRO premises on the dosing day and oversee the study procedures. To ensure compliance with the WHO guideline parameters, the official must visit at least once. EDCL will bear all relevant travel costs for EDCL officials only, and the CRO will arrange the necessary steps, for the trip. The CRO must include one person (from the local agent/partner) in travel costs in their offer to accompany the EDCL official.
- BE report should be prepared according to WHO format/ standard format which will be used to get certification for pre-qualification of WHO.
- The CRO must include the cost of the insurance policy and hospitalization in their financial offer. These costs must be covered by the CRO. EDCL will not provide any compensation for injury or fatality during the study.

4. Resource Requirements:


- At least 2 completed BE studies for hormones with female volunteer experience.
- CRO must have its own or contract with a bioanalytical laboratory.
- CRO must have GCP/GLP/ISO certified
- Accredited from any national or international regulatory body (WHO prequalified or recognised regulatory approvals i.e, USFDA, EMA, MHRA, TGA, etc.)

5. Procurement Method of the Service:

The firm's or consortium's selection process will be executed on the QCBS (Quality and Cost Based Selection) method.

6. Confidentiality:

All information related to the project, including designs, budgets, and other proprietary data, shall be treated as confidential and will not be disclosed to third parties without the written consent of both parties.



Handwritten signatures and initials at the bottom of the page, including a large signature that appears to be 'Samad'.

7. Termination:


Either party may terminate the contract with written notice if there is a material breach of the agreement. The terms of termination and any associated penalties or compensation will be outlined in the project contract.

8. Company Details:

The firm shall provide the necessary details mentioned in the Annexure to this document.

9. Conclusion:

These terms of reference outline the key aspects for the Selection of "CRO for Bioequivalence (BE) Study of Oral Contraceptive Pill". Both parties will work collaboratively to achieve the project objectives within the agreed-upon scope, timeline, and budget.

A series of handwritten signatures in black and blue ink, including a crossed-out signature.